Recursion Unveils LOWE Drug Discovery Software at the J.P. Morgan Healthcare Conference
January 08, 2024 10:59 ET
|
Recursion Pharmaceuticals
SAN FRANCISCO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today presented a demonstration...
Recursion to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8
January 03, 2024 08:00 ET
|
Recursion Pharmaceuticals
SALT LAKE CITY, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced that Chris...
Recursion and Enamine to Generate and Design Enriched Compound Libraries for Global Drug Discovery Industry
December 20, 2023 07:59 ET
|
Recursion Pharmaceuticals
KYIV, Ukraine and SALT LAKE CITY, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today...
Bayer and Recursion Focus Research Collaboration on Oncology
November 09, 2023 09:41 ET
|
Recursion Pharmaceuticals
Berlin, Germany and Salt Lake City, USA, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Bayer and US-based Recursion Pharmaceuticals, Inc., a clinical stage TechBio company decoding biology to industrialize drug...
Recursion Provides Business Updates and Reports Third Quarter 2023 Financial Results
November 09, 2023 07:58 ET
|
Recursion Pharmaceuticals
Entered into a collaboration with Tempus giving Recursion access to over 20 petabytes of multimodal oncology data for the purpose of training causal AI models together with Recursion’s proprietary...
Recursion to Participate in Upcoming Investor Conference
November 02, 2023 08:05 ET
|
Recursion Pharmaceuticals
SALT LAKE CITY, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its...
Recursion to Participate in Upcoming Investor Conferences
September 05, 2023 16:30 ET
|
Recursion Pharmaceuticals
SALT LAKE CITY, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its...
Recursion Announces Completion of Phase 1 Study for REC-3964 for Clostridioides Difficile Infection
September 05, 2023 07:59 ET
|
Recursion Pharmaceuticals
SALT LAKE CITY, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has...
Recursion Bridges the Protein and Chemical Space with Massive Protein-Ligand Interaction Predictions Spanning 36 Billion Compounds
August 08, 2023 08:00 ET
|
Recursion Pharmaceuticals
SALT LAKE CITY, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has...
Recursion Provides Business Updates and Reports Second Quarter 2023 Financial Results
August 08, 2023 07:58 ET
|
Recursion Pharmaceuticals
Deployed new digital chemistry technology, together with NVIDIA, to predict the ligand-protein interactions for approximately 36 billion compounds in the Enamine REAL Space, reported to be the world’s...